ENDARI® (L-Glutamine oral powder)

The FDA on July 7, 2017 approved ENDARI® for oral administration to reduce the acute complications of Sickle Cell disease, in adult and pediatric patients 5 years and older. ENDARI® is a product of Emmaus Medical, Inc.